Two little-hyped drugs developed by Human Genome Sciences Inc. and Sucampo Inc. (Nasdaq: SCMP) have won Food & Drug Administration nods.
The approval of HGS’ Raxibacumab as a treatment and prevention for inhaled anthrax and the supplemental approval of Sucampo’s Rescula, for glaucoma and ocular hypertension, both represents wins for Maryland biotech.
{iframe}http://www.bizjournals.com/washington/blog/techflash/2012/12/human-genome-sciences-sucampo-win-on.html?ana=e_du_pap&s=article_du&ed=2012-12-17{/iframe}